Cover Image
市場調查報告書

AmpliPhi Biosciences Corporation:產品平台分析

AmpliPhi Biosciences Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 295949
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
AmpliPhi Biosciences Corporation:產品平台分析 AmpliPhi Biosciences Corporation - Product Pipeline Review - 2015
出版日期: 2015年07月15日 內容資訊: 英文 40 Pages
簡介

AmpliPhi Biosciences Corporation (舊Targeted Genetics Corporation) 正在開發與商品化基於噬菌體的抗菌藥。

本報告提供AmpliPhi Biosciences Corporation的產品開發平台現狀及各開發階段比較分析,藥物簡介,開發平台的分析與最新趨勢,暫停中的計劃,開發中止的開發中產品的資訊等。

AmpliPhi Biosciences Corporation的基本資料

AmpliPhi Biosciences Corporation概要

  • 主要資訊
  • 企業資料

AmpliPhi Biosciences Corporation:R&D概要

  • 主要的治療範圍

AmpliPhi Biosciences Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

AmpliPhi Biosciences Corporation:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

AmpliPhi Biosciences Corporation:藥物簡介

  • tgAAG-76
  • AmpliPHAGE-001
  • AmpliPHAGE-002
  • AmpliPHAGE-004
  • AmpliPHAGE-001
  • AmpliPHAGE-002
  • AmpliPHAGE-004
  • 鮑氏不動桿菌生技藥品

AmpliPhi Biosciences Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

AmpliPhi Biosciences Corporation:最近的開發平台趨勢

AmpliPhi Biosciences Corporation:暫停中的計劃

AmpliPhi Biosciences Corporation:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • tg-AAVCF

AmpliPhi Biosciences Corporation:企業發表

AmpliPhi Biosciences Corporation:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07311CDB

Summary

Global Markets Direct's, 'AmpliPhi Biosciences Corporation - Product Pipeline Review - 2015', provides an overview of the AmpliPhi Biosciences Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AmpliPhi Biosciences Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of AmpliPhi Biosciences Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AmpliPhi Biosciences Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the AmpliPhi Biosciences Corporation's pipeline products

Reasons to buy

  • Evaluate AmpliPhi Biosciences Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AmpliPhi Biosciences Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AmpliPhi Biosciences Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AmpliPhi Biosciences Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AmpliPhi Biosciences Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AmpliPhi Biosciences Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AmpliPhi Biosciences Corporation Snapshot
    • AmpliPhi Biosciences Corporation Overview
    • Key Information
    • Key Facts
  • AmpliPhi Biosciences Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • AmpliPhi Biosciences Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • AmpliPhi Biosciences Corporation - Pipeline Products Glance
    • AmpliPhi Biosciences Corporation - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • AmpliPhi Biosciences Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • AmpliPhi Biosciences Corporation - Drug Profiles
    • tgAAG-76
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AmpliPHAGE-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AmpliPhage-002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AmpliPHAGE-004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AmpliPHAGE-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AmpliPhage-002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AmpliPHAGE-004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologics for Acinetobacter Baumanii
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biologics for Acinetobacter Baumanii
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AmpliPhi Biosciences Corporation - Pipeline Analysis
    • AmpliPhi Biosciences Corporation - Pipeline Products by Target
    • AmpliPhi Biosciences Corporation - Pipeline Products by Route of Administration
    • AmpliPhi Biosciences Corporation - Pipeline Products by Molecule Type
    • AmpliPhi Biosciences Corporation - Pipeline Products by Mechanism of Action
  • AmpliPhi Biosciences Corporation - Recent Pipeline Updates
  • AmpliPhi Biosciences Corporation - Dormant Projects
  • AmpliPhi Biosciences Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • tg-AAVCF
  • AmpliPhi Biosciences Corporation - Company Statement
  • AmpliPhi Biosciences Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AmpliPhi Biosciences Corporation, Key Information
  • AmpliPhi Biosciences Corporation, Key Facts
  • AmpliPhi Biosciences Corporation - Pipeline by Indication, 2015
  • AmpliPhi Biosciences Corporation - Pipeline by Stage of Development, 2015
  • AmpliPhi Biosciences Corporation - Monotherapy Products in Pipeline, 2015
  • AmpliPhi Biosciences Corporation - Out-Licensed Products in Pipeline, 2015
  • AmpliPhi Biosciences Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • AmpliPhi Biosciences Corporation - Phase I, 2015
  • AmpliPhi Biosciences Corporation - Preclinical, 2015
  • AmpliPhi Biosciences Corporation - Discovery, 2015
  • AmpliPhi Biosciences Corporation - Pipeline by Target, 2015
  • AmpliPhi Biosciences Corporation - Pipeline by Route of Administration, 2015
  • AmpliPhi Biosciences Corporation - Pipeline by Molecule Type, 2015
  • AmpliPhi Biosciences Corporation - Pipeline Products by Mechanism of Action, 2015
  • AmpliPhi Biosciences Corporation - Recent Pipeline Updates, 2015
  • AmpliPhi Biosciences Corporation - Dormant Developmental Projects,2015
  • AmpliPhi Biosciences Corporation - Discontinued Pipeline Products, 2015
  • AmpliPhi Biosciences Corporation, Other Locations
  • AmpliPhi Biosciences Corporation, Subsidiaries

List of Figures

  • AmpliPhi Biosciences Corporation - Pipeline by Top 10 Indication, 2015
  • AmpliPhi Biosciences Corporation - Pipeline by Stage of Development, 2015
  • AmpliPhi Biosciences Corporation - Monotherapy Products in Pipeline, 2015
  • AmpliPhi Biosciences Corporation - Pipeline by Top 10 Route of Administration, 2015
  • AmpliPhi Biosciences Corporation - Pipeline by Top 10 Molecule Type, 2015
Back to Top